Verastem (NASDAQ:VSTM) submits marketing authorization application (MAA) to the European Medicines Agency (EMA) for COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K), seeking approval for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and relapsed or refractory follicular lymphoma.
Shares are up 3% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.